• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Carfilzomib
    1 Drug classified under this active ingredient

    All the Active Ingredient Drugs

    partial basket chart

    Proteasome Inhibitor. Carfilzomib 60 mg/vial.
    SINGLE DOSE VIALS (lyophilized cake/ pwdr. for reconst.): 1×10,30,60 mg.
    Monother.: IV as a 10-min. infus. In Cycles 1 through 12, admin. Carfilzomib on two consecut. d., each wk. for three wks. follow. by a 12-d. rest period. Each 28-d. period is consid. one tmt. cycle. From Cycle 13, omit the Day 8 and 9 doses of Carfilzomib. Premedicate with dexamethasone 4 mg oral. or IV 30 min. to 4 hrs. before each Carfilzomib dose in Cycle 1, then as needed to help prevent infus. reactions. The recomm. start. dose of Carfilzomib is 20 mg/m² in Cycle 1 on Days 1 and 2. If tolerated, escalate the dose to 27 mg/m² on Day 8 of Cycle 1. Tmt. may cont. until dis. progres.  or unacceptab. toxicity occurs.
    For comb. with Dexamethasone and comb. with Lenalidomide and Dexamethasone: See lit.
    In comb. with dexamethasone or with lenalidomide plus dexamethasone for the tmt. of pts. with relapsed or refract. multiple myeloma who have received one to three prior lines of ther.
    As a single agent for the tmt. of pts. with multiple myeloma who have received at least two prior therapies includ. bortezomib and an immunomodulat. agent and have demonstr. dis. progres. on or within 60 d. of completion of the last ther. Approval is based on response rate. Clinical benefit, such as improv. in survival or sympt., has not been verified.
    C/I: Hypersens.